Can you share a case of a pediatric patient with severe AD, in whom you intensified therapy with dupilumab, and what the outcome was? How did the discussion evolve with the family and what end points were affected after how many months of therapy?
Can you share a case of a pediatric patient with severe AD, in whom you intensified therapy with dupilumab, and what the outcome was? How did the discussion evolve with the family and what end points were affected after how many months of therapy?
Presenter
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine